$CLVT

Tranche Update on Clarivate Plc's Equity Buyback Plan announced on December 16, 2024.

Clarivate Plc reported a tranche update on its equity buyback plan announced Dec. 16, 2024. From Apr. 1, 2026 to Jun. 30, 2026 it repurchased 0 shares for $0 million. Cumulatively it has bought back 63,042,889 shares, or 9.41%, for $242.63 million.

Original reporting
Published Jul 29, 2026, 9:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 4:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$CLVT
Neutral
medium confidence
Mentioned
$CLVT
Relevance
5/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$CLVTNeutralLow
01

Why it matters

The disclosure updates the buyback execution timeline and cumulative share count repurchased, which can influence sentiment around capital return but lacks new operational or financial catalysts.

02

Market read

Traders get a concrete datapoint on buyback progress, including a 0-share quarter and cumulative repurchases under the Dec 16, 2024 authorization.

03

What to watch

The article does not state whether the buyback is fully completed or if remaining authorization exists, nor does it provide the average repurchase price for the completed shares beyond total spend, limiting inference about future capital return pace.

Relevance 5/10Novelty 5/10Timing: latest buyback tranche update for Apr 1 to Jun 30, 2026

Background

Clarivate announced an equity buyback plan on Dec 16, 2024; this update reports repurchase activity over Apr 1 to Jun 30, 2026 and cumulative progress.

Company-level read

Ticker impact

$CLVTNeutralMedium confidence
Context

Clarivate reports it repurchased 0 shares in Apr 1 to Jun 30, 2026, completing 63,042,889 shares under its Dec 16, 2024 buyback plan.

Expected impact

Likely limited near-term impact; traders may view the pause in the latest tranche as neutral unless tied to future authorization changes.

Evidence & confidence

The article provides concrete buyback progress (0 shares in the most recent window, 63,042,889 shares total) but no new guidance, financing, or change to the authorization beyond the disclosed completion progress.

Market effects

Minimal read-across to the broader information services or IP/data analytics sector; this is company-specific capital return execution.

No clear regional spillover indicated by the article.

Limited global relevance; the disclosure is specific to Clarivate’s buyback activity.

Counterpoint

The 0-share repurchase in the latest window could signal management is waiting for better pricing or facing liquidity/market constraints, which may not be bullish.

Key entities

  • Clarivate Plc

    Provider of intelligence and workflow solutions; subject of the equity buyback tranche update.

Related articles

$CLVTMed

Clarivate Plc Q2 2026 Earnings Call Summary

Clarivate Plc (Q2 2026) discussed its Value Creation Plan to shift from transactional to recurring subscription revenue. It plans to divest the Life Sciences & Healthcare segment by year-end 2026, targeting about 92% recurring revenue pro forma. Management cited a $269m non-cash impairment, $70m one-time costs, and expects low-end FCF due to transaction and restructuring costs.

$CLVTMed

Clarivate Reports Second Quarter 2026 Results

Clarivate Plc (NYSE: CLVT) reported Q2 2026 results for the quarter ended June 30. Total revenue fell to $587.3 million from $621.4 million a year earlier, while organic revenues declined 1.5%. Net loss widened to $268.6 million due to a $221.7 million goodwill impairment; adjusted net income was $123.1 million. The company reaffirmed its 2026 outlook and cited a Life Sciences & Healthcare divestiture.

$CLVTMedAI 8/10

CLARIVATE PLC (CLVT): Results of Operations and Financial Condition

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991q22026earningsrelease.htm EX-99.1 Ex. 99.1 Q2 2026 Earnings Release 1 Clarivate Reports Second Quarter 2026 Results — Delivers continued progress on strategic and financial priorities through Value Creation Plan — — Sharpens focus and enhances financial profile wit

$CLVTMedAI 8/10

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Business

Clarivate (NYSE:CLVT) will sell its Life Sciences & Healthcare unit to Altaris for $600M to refocus on Academia & Government and Intellectual Property, according to company executives. Clarivate affirmed 2026 guidance midpoints except free cash flow, citing added transaction costs. Pro forma revenue and adjusted EBITDA would be down about $370M and $120M, but free cash flow is expected to hold.